By definition, idiopathic erythrocytosis (IE) applies to a group of patients characterised by having a measured RCM above their predicted normal range (an absolute erythrocytosis) and following investigation do not have a form of primary or secondary erythrocytosis. Patients with IE are heterogenous. The possibilities include physiological variation, 'early' polycythaemia vera (10-15% develop clear features of PV over a few years), unrecognized congenital erythrocytosis, unrecognized or unrecognizable secondary acquired erythrocytosis or a currently undescribed form of primary or secondary erythrocytosis. Patients are more commonly male with a median age at presentation of 55-60 years. Approximately half of the patients present with vascular occlusive complications. Retrospective evidence indicates that vascular occlusion occurs less frequently when the PCV is controlled at normal levels. Venesection is the treatment of choice to lower the PCV. As a general approach to management, all patients with a PCV above 0.54 should be venesected to a PCV less than 0.45. This target PCV should also apply to patients with lesser degrees of raised PCV who have additional other risk factors for vascular occlusion.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0369-8114(00)00025-0 | DOI Listing |
EJHaem
October 2024
Department of Medicine (DIMED) 1st Medical Clinic, Università degli Studi di Padova Padova Italy.
Genes Dis
January 2025
First Medical Clinic, Department of Medicine - DIMED, University of Padova, Padova 35128, Italy.
Cancers (Basel)
September 2024
Centro Nacional de Investigaciones Oncológicas, Complutense University, 28029 Madrid, Spain.
Front Med (Lausanne)
September 2024
Hematology Department, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Life (Basel)
April 2024
Department of Biomedical and Clinical Sciences Luigi Sacco, Luigi Sacco Hospital, University of Milan, 20157 Milan, Italy.
Background: Myeloproliferative neoplasms (MPNs) are often associated with splanchnic vein thrombosis (SVT). Not all the factors involved in the thrombotic tendency are currently known.
Objectives: This study aims to evaluate a possible association between ADAMTS13, von Willebrand factor (VWF), platelet microvesicles (MV), and factor VIII activity (FVIII:C) with thrombotic events in MPN patients.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!